Today: 19 May 2026
British American Tobacco share price ticks higher after buyback notice, with investors looking ahead
30 January 2026
1 min read

British American Tobacco share price ticks higher after buyback notice, with investors looking ahead

London, January 30, 2026, 08:02 GMT — Regular session.

Shares of British American Tobacco p.l.c. (BATS.L) ticked up 0.2% to 4,335 pence in early London trading on Friday following news of another share buyback. The stock closed Thursday at 4,327 pence and currently offers a dividend yield near 5.6%, according to recent figures.

The change is minor, but it comes as investors in high-yield consumer staples keep a close eye on cash returns. BAT’s daily buyback filings are standard procedure, but they provide the market with a real-time update on how fast the company is cutting its share count before important reporting deadlines.

BAT repurchased 131,672 shares on Jan. 29 at an average price of 4,346.8597 pence, with the highest price reaching 4,389 pence, a stock exchange filing showed. The company intends to cancel these shares. Buybacks like this typically reduce the number of shares on the market.

BAT disclosed the repurchase of 135,314 shares on Jan. 28, paying an average of 4,335.8629 pence each, again through UBS, with plans to cancel those shares. This buyback is part of a programme the company announced on March 18, 2024.

Buybacks can boost earnings per share by shrinking the share count, but the impact hinges on how quickly companies repurchase and the stock’s price level. Traders keep an eye on whether buybacks siphon funds away from dividends or debt repayment.

The sector’s outlook stays complicated, especially in the U.S., where tobacco firms are betting on new nicotine products as cigarette sales slide. Altria, a key player, highlighted a “double duty drawback” — a tax rule letting companies recoup some excise taxes on exports of similar goods — as a near-term profit boost. Salvatore Mancuso, Altria’s finance chief, told Reuters it would be “foolish” not to take advantage of this. Meanwhile, Bernstein analysts painted a “challenging picture” as companies scramble for growth in alternatives. Reuters

BAT plans its next quarterly dividend payout for Feb. 4 on the London and Johannesburg registers. The New York-listed ADS will see its payment made on Feb. 9, as per the company’s dividend schedule.

BAT is set to release its 2025 preliminary results on Feb. 12 at 7:00 a.m. GMT. A webcast and Q&A session will follow at 9:30 a.m. GMT, according to the company’s results centre.

Stock Market Today

  • Top 5 Blue-Chip Stocks to Boost Portfolio Returns in 2026
    May 19, 2026, 9:58 AM EDT. The Dow Jones Industrial Average briefly surpassed 50,000 in May, highlighting positive momentum supported by its position above key moving averages. Analysts recommend five blue-chip stocks with strong Zacks Rank #2 (Buy) ratings to enhance portfolios in 2026: Cisco Systems (CSCO), Salesforce (CRM), Apple (AAPL), Visa (V), and Chevron (CVX). Cisco benefits from robust AI infrastructure demand and restructuring to focus on growth areas. Salesforce is expanding generative AI offerings through Einstein GPT and strategic investments. These stocks are favored for potential revenue and earnings growth amid evolving technological and economic trends.

Latest articles

Bakkt Up Early After Director Buys $4.85M in Shares

Bakkt Up Early After Director Buys $4.85M in Shares

19 May 2026
Bakkt shares jumped 14.2% to $9.96 in pre-market trading Tuesday after a filing showed director Michael Alfred’s vehicle bought $4.85 million in stock. SEC documents said Alfred acquired 585,000 shares last week via Alpine Fox LP. CEO Akshay Naheta exercised options for 33,557 shares at $10 each. Bakkt recently reported Q1 revenue of $243.6 million, down sharply from a year earlier.
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

19 May 2026
Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.

Popular

Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

18 May 2026
Intel shares rose 0.3% to $109.10 in early New York trading Monday after last week’s selloff, as analysts raised price targets and President Trump commented on the U.S. government’s 10% stake, now valued above $50 billion. First-quarter revenue climbed 7% to $13.6 billion, with Data Center and AI sales up 22%. The iShares Semiconductor ETF fell 0.9%. Intel’s server CPU market share dropped to 54.9% in Q1, according to UBS.
Snowflake stock slides nearly 8% in software rout; traders brace for next catalyst
Previous Story

Snowflake stock slides nearly 8% in software rout; traders brace for next catalyst

GSK share price dips in London as Exdensur rollout and Feb 4 results loom
Next Story

GSK share price dips in London as Exdensur rollout and Feb 4 results loom

Go toTop